TORONTO, Dec. 8, 2020 /PRNewswire-PRWeb/ -- While solid tumor biopsies remain the standard for the interrogation of the cancer genome, the advent of liquid biopsies and multi-region tissue sampling has demonstrated that there can be more to a cancer's genotypic profile than that found in a single tissue biopsy. NeXT Liquid Biopsy™, a first-of-its-kind, high-performance, exome-wide liquid biopsy assay, is designed to complement ImmunoID NeXT™, providing a unique ability to further evaluate the cancer ecosystem and advance the development of next-generation therapies.
NeXT Liquid Biopsy enables investigation into key applications, such as spatial and temporal heterogeneity of the tumor, clonal evolution and tumor dynamics in response to therapies, and mechanisms of acquired resistance. NeXT Liquid Biopsy is purpose-built to navigate the inherent variability of circulating tumor DNA (ctDNA), elucidating key areas of tumor biology not often addressed by targeted, commercially available liquid biopsy panels.
To enable sensitive variant detection across 20,000 genes, this enhanced exome assay and chemistry achieves high sequencing depth of approximately 2,000x exome-wide, with additional boosted depth, 5,000x, for 247 cancer-related genes. Personalis has developed a computational pipeline optimized to lower the noise floor for variant detection, providing sensitive monitoring and de novo detection of variants over multiple time points.
Join expert speakers from Personalis, Sean Michael Boyle, PhD, Senior Director, Bioinformatics Applications; and Dan Norton, MBA, Senior Product Manager, in a live webinar on Thursday, December 17, 2020 for a discussion of the data demonstrating the genomic profiling and assay performance enabled by NeXT Liquid Biopsy through the evaluation of various reference standards and actual patient samples. Participants can choose from 2 live broadcasts at 8am EST (1pm GMT/UK) and 4pm EST.
For more information, or to register for this event, visit NeXT Liquid Biopsy: A High-Performance, Exome-Wide Liquid Biopsy Assay to Study Tumor Dynamics.
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
Karen Lim, Xtalks, (416) 977-6555 227, [email protected]